MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $5.47 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,778 shares of the biopharmaceutical company’s stock after selling 309 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Halozyme Therapeutics were worth $5,474,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Wealth Preservation Advisors LLC acquired a new stake in Halozyme Therapeutics during the 1st quarter valued at $32,000. SVB Wealth LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth $33,000. Bessemer Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 207 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $29,000. Finally, Brooklyn Investment Group lifted its holdings in shares of Halozyme Therapeutics by 1,558.1% during the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 670 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $77.53 on Friday. The stock’s 50 day moving average is $64.65 and its 200 day moving average is $60.32. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The firm has a market cap of $9.07 billion, a P/E ratio of 17.74, a P/E/G ratio of 0.42 and a beta of 1.19. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $77.58.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $325.72 million during the quarter, compared to analysts’ expectations of $282.66 million. During the same quarter last year, the firm posted $0.91 earnings per share. The firm’s revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $46,598,493.69. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Nicole Labrosse sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the completion of the transaction, the chief financial officer directly owned 24,306 shares in the company, valued at approximately $1,840,207.26. This trade represents a 45.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 124,000 shares of company stock valued at $7,830,320. 2.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on HALO shares. Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 2nd. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a “neutral” rating and a $55.00 price target for the company. JMP Securities boosted their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Finally, HC Wainwright boosted their price target on Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $67.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.